Vertex Pharmaceuticals will acquire therapy developer Alpine Immune Sciences for $65 per share, or about $4.9 billion in cash, the companies said on Wednesday.
With the acquisition, Vertex will add Alpine's portfolio of protein-based immunotherapies to treat autoimmune and inflammatory diseases.
The transaction, approved by Vertex and Alpine's boards, is expected to close in the second quarter of 2024.
https://finance.yahoo.com/news/1-vertex-pharmaceuticals-buy-alpine-201609049.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.